The present invention is directed to a bariatric device and method of causing at least partial satiety in a patient. In particular, the present invention is directed to a bariatric device and a method of causing at least partial satiety in a patient by a noninvasive or minimally invasive technique.
Obesity is a large and increasing problem in the United States and worldwide. In round numbers, from the period encompassing the year 1990 to the period encompassing the year 2000, the prevalence of overweight people (BMI greater than 25) increased from 56 percent of United States adults to 65 percent and the prevalence of obese adults (BMI greater than 30) increased from 23 percent to 30 percent. Likewise, the prevalence of overweight children and adolescents (ages 6-19 years) increased from 11 percent in the period encompassing the year 1990 to 16 percent in the period encompassing the year 2000. The increasing prevalence of overweight among children and adolescents will make the problem even greater when they reach adulthood. The problem is not limited to the United States. Between 10 percent and 20 percent of European men are obese and between 10 percent and 25 percent of European women are obese. Numerous medical conditions are made worse by obesity including Type II diabetes, stroke, gallbladder disease and various forms of cancer. Approximately 500,000 people in North America and Western Europe are estimated to die from obesity-related diseases every year and obesity is estimated to affect more than one billion adults worldwide. Therefore, there is a pressing and unmet need for a solution to the epidemic problem.
Various techniques are known for reducing obesity in patients. Known techniques tend to be based upon restricting food movement and/or nutrient absorption. One example is gastric bypass surgery on the patient, which is highly invasive. The goal of such surgery is to form a pouch from a portion of the stomach to reduce the volume of the space in the stomach receiving food. When the patient ingests food, the pouch is filled which stretches the stomach wall and produces satiety. One difficulty with such procedure is that it requires food to fill the pouch to create satiety. As a result, dietary restrictions are required for effective operation of the pouch. Such restrictions include withholding of liquids during meals to avoid washing the food from the pouch. Also, liquids with substantial calories tend to pass through the pouch without creating substantial satiety. Moreover, the opening from the pouch tends to become enlarged over time, thus allowing more food to pass while achieving reduced satiety. Thus, patients undergoing such surgical techniques often experience gradual weight gain over time.
Alternative weight loss devices and methods have been proposed. However, such devices and methods may be difficult to place in the patient, have questionable efficacy, and may cause undesirable side effects.
The present invention utilizes a new principle of implied satiation. The present invention provides a bariatric device and method of causing satiety in a patient that augments the natural response of the body. This may be accomplished using a non-invasive or minimally invasive procedure with a device that may be removable or absorbable. Moreover, satiety may be caused in a manner that does not interfere with other body functions, such as operation of normal reflux mechanism, bile ducts, taking of medications, and the like. The implied satiation technique of the present invention does not rely on either the restrictive or malabsorptive techniques of the prior art.
A bariatric device, according to an aspect of the invention, includes a body having a wall defining a lumen. The wall is configured to generally conform to the shape and size of the proximal cardiac portion of the stomach and to exert pressure on the proximal cardiac portion of the stomach in the absence of food, thereby influencing a neurohormonal feedback mechanism of the patient to cause at least partial satiety by augmenting fullness caused by food and simulating fullness in the absence of food. The lumen is substantially unrestricted. At least one fixation mechanism resists distal migration of the body.
The wall may be made from a self-extendable silicone-coated material. The wall may be flared to thereby conform to the cardiac notch of the proximal cardiac portion of the stomach. The body may be generally frusto-conical in shape. The wall may exert a generally consistent radial pressure on the proximal cardiac portion of the stomach. The wall may be at least partially absorbable.
The fixation system may include barbs, V-shaped appendages, metallic anchors extending radially from said body, staples and/or sutures. The wall may be compressible for deployment through the esophagus. The wall may be removable.
A method of causing at least partial satiety in a recipient, according to an aspect of the invention, includes positioning a body at a proximal cardiac portion of the stomach and fixing the body to the recipient to resist migration of the body. The body has a wall defining a lumen and is configured to the size and shape of the proximal cardiac portion of the stomach. The lumen is substantially unrestricted. Pressure is exerted with the wall on the proximal cardiac portion of the stomach in the absence of food, thereby influencing a neurohormonal feedback mechanism of the patient to cause at least partial satiety by augmenting fullness caused by food and simulating fullness in the absence of food.
Anti-nausea medication may be administered to the recipient at least during initial deployment of said body. Nutritional supplements may be administered to the recipient. The body may be generally frusto-conical in shape. A generally consistent radial pressure may be exerted with the wall to the proximal cardiac portion of the stomach. The wall may be at least partially absorbable.
The fixation system may include barbs, V-shaped appendages, metallic anchors extending radially from said body, staples and/or sutures. The wall may be compressed and the body deployed through a recipient's esophagus. The body may be removed after the recipient has experienced sufficient weight loss.
Thus, it can be seen that embodiments of the present invention provide an implied satietor and implied satiation method that does not require food to generate the satiety through the neurohormonal mechanism of the body. This advantageously produces at least partial satiety in the patient in the absence of food, as well as augmenting fullness caused by food during the ingestion of the food. Moreover, because satiety is not caused by food, the patient would not necessarily need to be subject to dietary restrictions, such as withholding of liquids during meals or withholding of liquids having substantial calories.
Moreover, in contrast to surgical procedures, embodiments of the present invention provide a bariatric device and method of causing at least partial satiety that is minimally invasive and which avoids many of the potential side effects of gastric bypass surgery and other surgical procedures, such as adjustable gastric banding, and the like. Also, because of the placement of the device, there is no interference with operation of gastric functions, such as with the bile ducts, and the like. Further, as previously noted, the bariatric device can be adapted to allow the gastro-esophageal junction to function normally without any significant interference or impediment. Also, embodiments of the invention provide a bariatric device and method of inducing at least partial satiety in the patient that does not operate on the basis of causing flu-like symptoms in the patient in a thwarted effort to attempt to induce the patient to eat less, such as may occur by the placement of devices in the patient's duodenum, or the like.
Additionally, in contrast to pouches formed in gastric bypass surgery, embodiments of the present invention do not include a discharge opening that is subject to enlargement with the passage of time, thereby eliminating at least one source of gradual weight gain in patients undergoing gastric bypass surgery.
Moreover, because it is a non-invasive or minimally invasive procedure, embodiments of the present invention may be applied not only to morbidly obese patients, but also to obese patients, overweight patients, adolescents, and potentially even children.
Thus, it is seen that the present invention is embodied in a bariatric device and method including a body having an expandable wall, which evokes normal neurohormonal responses associated with fullness or satiety. The body wall does so by acting on one or more portions of the distal esophagus and/or the cardia of the patient. The normal filling sensation of the stomach is augmented and amplified. Further, it has been found that the body appears to have a “satiety continuum” where a person transitions from hungry, which is on one end of the continuum or spectrum where there is a lack of satiety, to lacking hunger or being satisfied after eating and to being full with continued consumption. If the person continues to eat to the point of overeating, the person then becomes nauseous, which represents the other end of the continuum. As the pressure applied to the distal esophagus and/or the cardia of a patient is increased, the further along the patient will be on this “continuum” or spectrum. Ideally, then for an extremely overweight person, the bariatric device of the present invention may be best used if sufficient pressure is applied so that the patient is on the nausea end of the spectrum or just below at a “sub-nausea” point.
These and other objects, advantages and features of this invention will become apparent upon review of the following specification in conjunction with the drawings.
Referring now specifically to the drawings, and the illustrative embodiments depicted therein, a bariatric device, or implied satietor, 15, which causes satiety by acting on the abdominal portion of the esophagus, and/or the esophageal-gastric junction and/or the proximal cardiac portion of the stomach, is illustrated in
Wall 17 is configured to exert an outward pressure, typically a generally radial outward pressure, at the abdominal portion of the esophagus, the esophageal-gastric junction and/or the cardia of the patient. This may be accomplished, for example, by configuring the wall to have a proximal portion 17a to create an interference fit with the abdominal portion of the esophagus and/or a central portion 17b configured to create an interference fit with the esophageal-gastric junction and/or a distal portion 17c configured to create an interference fit with the patient's cardia. The pressure exerted by wall portions 17a, 17b and/or 17c influences the neurohormonal feedback mechanism present at the esophagus and/or stomach to cause at least partial satiety. As will be discussed in more detail below, the pressure exerted by the extendable wall may be fixed or adjustable. The force that influences the neurohormonal feedback mechanism present at the abdominal portion of the esophagus, the esophageal-gastric junction and/or the cardiac portion of the stomach is intended to be relatively consistent over as large an area as reasonably possible. The force exerted by the wall of the bariatric device is believed to activate stretch receptors located in the abdominal portion of the esophagus, the esophageal junction and/or the cardia. In contrast to prior proposed devices, which require that the patient ingest food in order to influence neurohormonal feedback mechanisms, bariatric device 15 simulates fullness in the absence of food. It also augments fullness caused by food.
This interference fit may be created by a self-extendable, or self-expanding, wall. Alternatively, it may be created by an extendable wall, such as a balloon-extendable wall. The extended wall diameter is chosen so that it is somewhat oversized compared to the diameter of the conduit in which it is positioned, namely, the abdominal portion of the esophagus, the esophageal-gastric junction and/or the cardia. A self-extendable wall may be, by way of example, formed from a material, such as metal, fibers or fibrous materials, including carbon fibers, and may be a wall made from a self-extendable silicone-coated material. For example, the wall may be formed from a metal sheet, such as a Nitinol sheet, formed for example, by laser cutting, or from a coil or lattice structure formed from a metal or carbon fiber, which may be encapsulated or embedded in an insert polymer, such as silicone or the like. Alternatively, the wall may be extended by a balloon or fluid extendable reservoir expanding the wall outwardly, including generally radially outwardly, to a position firmly against the wall of the conduit in which the body is inserted. This inflation may be accomplished endoscopically with a blunt needle or with a control as will be discussed in more detail below.
As can be seen in
The narrow portion of lumen 18, which generally is the portion in the patient's esophagus, may have a length that is no longer required to provide enough force to produce satiety. In the illustrative embodiment, the narrow portion of lumen 18 is less than 9 cm in length. In certain embodiments, the narrow portion of lumen 18 is in the range of between 6 cm and 7 cm in length. This reduces the tendency of food to get caught in the lumen as well as any interference with peristalsis of the esophagus while producing force over a sufficient surface area to produce satiety.
In the embodiment illustrated in
Bariatric device 15 may include a fixation system 21, which is capable of resisting distal migration of the device. Fixation system 21 may include a series of anchors 22 illustrated as a series of V-shaped downwardly directed appendages from wall 17. Alternatively, the anchors may be in the shape of downwardly directed barbs or hooks, metallic anchors extending radially from said body, or the like. Such arrangement provides fixation against migration, typically distal migration, while allowing the device to be easily removed from the patient because the anchors may be configured to provide less resistance to proximal movement. In the embodiment illustrated in
A bariatric device 115 includes a wall 117 having a proximal wall portion 117a that applies outward pressure, such as generally radially outward pressure, to the abdominal portion of the esophagus, a distal portion 117c that applies outward pressure, such as generally radially outward pressure, to the proximal cardiac portion of the stomach, and a middle portion 117b that is positioned at the esophageal-gastric junction (
An alternative bariatric device 215 includes a body 216 having an expandable wall 217 (
As can be seen in
As illustrated in
Control 29 may provide for a temporal adjustment of the amount of pressure exerted by bariatric device 215 on the patient's distal esophagus and/or proximal stomach. By way of example, control 29 may include an algorithm that causes fluid to be transferred from fluid reservoir 30 to fluid chamber 24 of the device 215 in order to increase the amount of pressure, typically radial pressure, exerted by wall 217 during general waking hours of the patient when satiety is desired. Control 29 can further be programmed to transfer fluid from reservoir 24 to reservoir 30 during periods of time when the patient is expected to be sleeping and satiety is not required. Patient control 31 may, alternatively, allow manual adjustment of the amount of force exerted by wall 214 of device 215. For example, when the patient retires at night, the patient may operate user control 31 in order to instruct control 29 to transfer fluid from chamber 24 to fluid reservoir 30, thereby reducing pressure exerted by wall 217. When the patient awakes, the patient may then utilize user control 31 in order to cause control 29 to increase the amount of pressure exerted by wall 217. This temporal control of the amount of force exerted by wall 217 should overcome any potential tachy phylaxis that may result in the diminishing response of the neurohormonal system of the patient to the force exerted by wall 217. Alternatively, the temporal control may be utilized, where appropriate, to adjust the amount of pressure with respect to eating times of the patient, or the like. Control 29 may, alternatively, monitor certain hormonal levels of the patient in order to determine when the patient is expected to eat a meal and may even be a self-learning control system in order to learn the variations in the patient's hormonal levels.
An alternative bariatric device 315 may further include a restriction component 33 restricting discharge of food from lumen 18 (
An alternative bariatric device 515 may include a body 516 having a wall 517 including an anti-reflux component 35 (
An alternative bariatric device 615 includes a body 616 having a wall 617 that is self-expandable at a proximal portion 617a, a middle portion 617b and a distal portion 617c, the latter being configured to the cardiac notch of the patient (
An alternative bariatric device 715 illustrated in
Anchors may be positioned at various locations along the exterior of the wall of the device. For an example, an alternative bariatric device 815 is illustrated in
An alternative bariatric device 915 illustrated in
As noted above, the non-self-expanding portion of bariatric device of the present invention may be formed from discrete wall portions. Referring to
In the illustrated embodiment, the central portion 1017b of the body 1016 is formed from discrete wall portions 1020, which connect the proximal and distal portions 1017a, 1017c of wall 1017 together. Wall portions 1020 may act as tension members between the distal portion and the proximal portion and may further act as compression members to maintain the distal and proximal portions at a desired spacing, but which do not exert any significant outward or radial pressure on the gastro-esophageal junction. Wall portions 1020 may be generally equal in size and evenly spaced around the perimeter of body 1016 or may be unevenly spaced and, further, may have different widths and lengths. For example, the lengths of the wall portions may fall in a range of 0.75 cm to 1.5 cm. The number of wall portions may vary, with the illustrated embodiment depicting four wall portions that are generally evenly spaced around the perimeter of body 1016.
As noted above, wall portions 1020 optionally form a non-self-expanding portion of wall 1017 and align with the gastro-esophageal junction to allow the junction to function normally. The spaces between the wall portions 1020 may comprise holes or openings or may be filled by a flexible membrane or flaccid material.
In addition, wall portions 1020 may provide fixation points, for example, for sutures to secure device 1015 at or near the gastro-esophageal junction in which case the material forming wall portions 1020 may formed from a relatively stiff material, such as fibers or fibrous material, for example, embedded in silicone, for example.
Further, the upper open end or entrance of body 1016 may be flared outwardly to bear or seal against the esophageal wall to essentially close off the space or gap between device 1015 and the esophagus.
Various delivery systems may be utilized to deliver any of the bariatric devices 15-1015 to the patient. Such a delivery system may include a tube device (not shown) into which the bariatric device is compressed. The tube device may be a stiff or flexible tube and be sized and shaped to easily fit within the patient's esophagus. Such a delivery system includes a deployment mechanism (not shown) to retract the bariatric device from the tube. As the bariatric device is removed from the tube, it assumes its expanded form. If a self-expanding wall is utilized, the bariatric device will assert pressure, such as a generally radial pressure, on the distal esophagus and/or the cardia of the patient when removed from the tube. If an expandable wall is utilized, such as a bladder, the bladder is inflated in order to exert pressure. Various markers, such as fluorescent markers, may be applied to the wall of the bariatric device in order to allow for fluoroscopic assist in the placement of the device.
A method 50 may be provided for monitoring and, if desired, adjusting the amount of satiety produced by the bariatric device and method (
If it is determined at 56 that an appropriate level of satiety is not being obtained, the process returns to 52 where a different level of pressure may be adjusted by the body. The adjustment of pressure may be in the form of adding or subtracting fluid from a bariatric device having an expandable wall by the use of a chamber 24. Alternatively, the adjustment of the pressure may be in the form of deploying a different size or characteristic device, which is self-expandable and applies a different force to the patient through the self-expandable wall. The amount of satiety may be different for different patients. For example, a patient who is overweight may require a particular level of pressure, whereas a more obese, such as a morbidly obese, patient may require a higher level of satiety. Likewise, a child or an adolescent may require different levels of pressure. The ability to obtain immediate feedback on satiety strength allows the efficacy of the system to be established at deployment rather than monitoring the patient for weight loss and adjusting it after the patient has lost either too much or too little weight.
Alternately, the amount of satiety can be gauged by where the patient falls on the satiety continuum—that is whether they are hungry, satisfied, full or even nauseous. For a morbidly obese person, it may be desirable to apply sufficient pressure so that the patient is nauseous and then optionally reduced slightly so that the patient just below being nauseated or at a sub-nauseous level. This may be particularly useful when a remote control is being used in combination with an adjustable device where the patient may themselves adjust the level of pressure to maintain their desired or a prescribed level of satiety.
Any of the bariatric devices 15-1015 may be used as part of a multi-disciplinary comprehensive program. This may include the adjustment of medications as the patient experiences weight loss. For example, for patients taking diabetic medications, less insulin may be required as a patient loses weight. Also, blood pressure medications and other medications may be adjusted as the patient loses weight.
Because of the ability of the bariatric device 15-1015 to cause satiety, it is possible, in certain patients, that the patient will require nutritional supplements, such as protein liquids, in order to ensure adequate nutritional needs, such as protein intake. Also, anti-nausea medications may be given to the patient, especially at the beginning of the placement. This is because a bariatric device, according to the invention, may cause nausea at the beginning of the placement.
In order to reduce the likelihood of food getting caught in the lumen and in order to minimize interference with natural peristalsis in the esophagus, the length of the lumen is generally kept below 9 cm. In most embodiments, the length of the lumen is in the range of approximately 6 cm to approximately 7 cm. Widened portions of the body, such as distal portions 17c-1017c, are not considered part of the lumen for determining the length of the lumen. The expandable wall, whether self-expanding or balloon-expandable, should provide consistent pressure over as large an area as possible in order to induce adequate satiety, consistent with an effort to keep the lumen as short as possible.
Thus, it is seen that the present invention introduces a new category of weight loss techniques: implied satiation. The invention advantageously utilizes stretch receptors, such as those located at the abdominal portion of the esophagus and/or esophageal-gastric junction and/or the cardiac portion of the stomach of the patient to cause satiety. In contrast to gastric bypass surgery and adjustable gastric bands, the present invention does not require surgical intervention. In that regard, the present invention provides a non-invasive or minimally invasive alternative. However, the invention may be utilized in combination with known restrictive and/or malabsorptive techniques, such as gastric bypass surgery and adjustable gastric bands to further help the patient lose weight. Advantageously, the present invention may be applied to patients who are contraindicated for surgery, such as those with mildly high obesity and for those at risk for surgery. Also, the invention may be used to achieve sufficient weight loss in morbidly obese patients to stabilize the patient for gastric bypass surgery. Moreover, the present invention may be properly sized for use with children and adolescence. Thus, the present invention provides a non-intrusive or minimally intrusive technique for addressing the increasing epidemic of obesity in adolescents and children, as well as adults.
The present invention also comprehends an implied satietor that is capable of exerting pressure at the patient's abdominal portion of the esophagus, esophageal-gastric junction and/or cardia, such as by suitable dimensioning of a self-expanding wall or by a mechanism for expanding the wall outwardly. Examples of such a mechanism may be a bladder mechanism whereby the wall could exert varying pressures. The present invention also has the capability of assisting in reducing esophageal leakage. This may further enhance the use of the invention in combination with other techniques, such as gastric bypass surgery, esophageal tumors, and the like. In addition to influencing the neurohormonal feedback mechanism present at the abdominal portion of the esophagus, the present invention is capable of resisting egress from the lumen of the satiety device. This provides additional benefit to certain patients by resisting their ability to ingest food beyond satiety. Because the device may be inserted endoscopically with fluoroscopic assist, the device may be suitably and accurately positioned at the desired location within the patient's esophagus, esophageal-gastric junction and/or cardia and adjustments made to the satiety device as required. Moreover, the device may be subsequently removed from the patient if indicated. The use of various fixation systems allow the device to be positioned at or near the abdominal portion of the esophagus, the esophageal-gastric junction and/or the cardia while resisting distal migration of the device. Moreover, the use of such fixation system may allow for the satiety device to be readily removed from the patient.
Evidence of the viability of the invention can be seen by its principle having been reduced to practice and found to cause weight loss in patients. The patients, who ranged from non-obese to morbidly obese, lost weight, generally over a one or two week period during which the device was in place. The patients experienced some initial nausea. They reported satiety throughout placement of the device. When the device was no longer present, the patients regained hunger.
Changes and modifications in the specifically described embodiments can be carried out without departing from the principles of the invention, which is intended to be limited only by the scope of the appended claims, as interpreted according to the principles of patent law including the doctrine of equivalents.
The present invention is a continuation of prior application Ser. No. 15/805,495, filed Nov. 7, 2017, which is a continuation of application Ser. No. 15/211,034 filed Jul. 15, 2016, now U.S. Pat. No. 9,839,545, which is a continuation of U.S. patent application Ser. No. 14/920,403, filed on Oct. 22, 2015, now U.S. Pat. No. 9,414,948, which is a continuation of U.S. patent application Ser. No. 14/314,444, filed on Jun. 25, 2014, now U.S. Pat. No. 9,198,789, which is a continuation of U.S. patent application Ser. No. 14/142,131, filed on Dec. 27, 2013, now U.S. Pat. No. 8,801,599, which is a continuation of U.S. patent application Ser. No. 13/331,425 filed on Dec. 20, 2011, now U.S. Pat. No. 8,672,831, which is a continuation of U.S. patent application Ser. No. 12/915,952, filed on Oct. 29, 2010, now U.S. Pat. No. 8,100,931, which is a continuation of U.S. patent application Ser. No. 11/463,192, filed on Aug. 8, 2006, now U.S. Pat. No. 7,846,174, which is continuation-in-part application of International Application No. PCT/US2005/036991, filed on Oct. 13, 2005, entitled BARIATRIC DEVICE AND METHOD, which claims the benefit of Ser. No. 60/619,308 filed on Oct. 15, 2004; and claims the benefit of Ser. No. 60/632,147 filed on Dec. 1, 2004; and claims the benefit of Ser. No. 60/636,845 filed on Dec. 15, 2004; and claims the benefit of Ser. No. 60/711,310 filed on Aug. 25, 2005, the disclosures of which are incorporated herein in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4403604 | Wilkinson et al. | Sep 1983 | A |
4607618 | Angelchik | Aug 1986 | A |
5234454 | Bangs | Aug 1993 | A |
5306300 | Berry | Apr 1994 | A |
5366504 | Andersen et al. | Nov 1994 | A |
5507755 | Gresl et al. | Apr 1996 | A |
5662713 | Andersen et al. | Sep 1997 | A |
5741279 | Gordon et al. | Apr 1998 | A |
5820584 | Crabb | Oct 1998 | A |
6146416 | Andersen et al. | Nov 2000 | A |
6264700 | Kilcoyne et al. | Jul 2001 | B1 |
6280415 | Johnson | Aug 2001 | B1 |
6312437 | Kortenbach | Nov 2001 | B1 |
6355070 | Andersen et al. | Mar 2002 | B1 |
6398802 | Yee | Jun 2002 | B1 |
6432040 | Meah | Aug 2002 | B1 |
6447533 | Adams | Sep 2002 | B1 |
6468298 | Pelton | Oct 2002 | B1 |
6544291 | Taylor | Apr 2003 | B2 |
6558400 | Deem et al. | May 2003 | B2 |
6572627 | Gabbay | Jun 2003 | B2 |
6656194 | Gannoe et al. | Dec 2003 | B1 |
6675809 | Stack et al. | Jan 2004 | B2 |
6736828 | Adams et al. | May 2004 | B1 |
6740121 | Geitz | May 2004 | B2 |
6746460 | Gannoe et al. | Jun 2004 | B2 |
6755869 | Geitz | Jun 2004 | B2 |
6773440 | Gannoe et al. | Aug 2004 | B2 |
6800081 | Parodi | Oct 2004 | B2 |
6802868 | Silverman et al. | Oct 2004 | B2 |
6845776 | Stack et al. | Jan 2005 | B2 |
6916332 | Adams | Jul 2005 | B2 |
6960233 | Berg et al. | Nov 2005 | B1 |
6981978 | Gannoe | Jan 2006 | B2 |
6994095 | Burnett | Feb 2006 | B2 |
6994715 | Gannoe et al. | Feb 2006 | B2 |
7025791 | Levine et al. | Apr 2006 | B2 |
7033373 | de la Torre et al. | Apr 2006 | B2 |
7033384 | Gannoe et al. | Apr 2006 | B2 |
7037344 | Kagan et al. | May 2006 | B2 |
7044979 | Silverman et al. | May 2006 | B2 |
7066945 | Hashiba et al. | Jun 2006 | B2 |
7083629 | Weller et al. | Aug 2006 | B2 |
7083630 | DeVries et al. | Aug 2006 | B2 |
7087088 | Berg et al. | Aug 2006 | B2 |
7097650 | Weller et al. | Aug 2006 | B2 |
7097665 | Stack et al. | Aug 2006 | B2 |
7111627 | Stack et al. | Sep 2006 | B2 |
7146984 | Stack et al. | Dec 2006 | B2 |
7152607 | Stack et al. | Dec 2006 | B2 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7211114 | Bessler et et al. | May 2007 | B2 |
7220284 | Kagan et al. | May 2007 | B2 |
7232461 | Ramer | Jun 2007 | B2 |
7347875 | Levine et al. | Mar 2008 | B2 |
7431725 | Stack et al. | Oct 2008 | B2 |
7445010 | Kugler et al. | Nov 2008 | B2 |
7449024 | Stafford | Nov 2008 | B2 |
7678068 | Levine et al. | Mar 2010 | B2 |
7682330 | Meade et al. | Mar 2010 | B2 |
7704264 | Ewers et al. | Apr 2010 | B2 |
7708752 | Durgin | May 2010 | B2 |
7753870 | Demarais et al. | Jul 2010 | B2 |
7771382 | Levine et al. | Aug 2010 | B2 |
7794447 | Dann et al. | Sep 2010 | B2 |
7815589 | Meade et al. | Oct 2010 | B2 |
7815591 | Levine et al. | Oct 2010 | B2 |
7846174 | Baker | Dec 2010 | B2 |
7922650 | McWeeney et al. | Apr 2011 | B2 |
7976488 | Levine et al. | Jul 2011 | B2 |
7981163 | Meade et al. | Jul 2011 | B2 |
8029455 | Stack et al. | Oct 2011 | B2 |
8043355 | Shin et al. | Oct 2011 | B2 |
8100931 | Baker et al. | Jan 2012 | B2 |
8137301 | Levine et al. | Mar 2012 | B2 |
8142513 | Shalon et al. | Mar 2012 | B2 |
8162871 | Levine et al. | Apr 2012 | B2 |
8252009 | Weller | Aug 2012 | B2 |
8282598 | Belhe et al. | Oct 2012 | B2 |
8372087 | Baker et al. | Feb 2013 | B2 |
8447403 | Sharma et al. | May 2013 | B2 |
8506477 | Waller et al. | Aug 2013 | B2 |
8529431 | Baker et al. | Sep 2013 | B2 |
8556956 | Cully et al. | Oct 2013 | B2 |
8672831 | Baker et al. | Mar 2014 | B2 |
8721528 | Ho et al. | May 2014 | B2 |
8778011 | Ryan | Jul 2014 | B2 |
8784436 | Ho et al. | Jul 2014 | B2 |
8801599 | Baker et al. | Aug 2014 | B2 |
8894670 | Baker et al. | Nov 2014 | B2 |
9055998 | Baker | Jun 2015 | B2 |
9060844 | Kagan et al. | Jun 2015 | B2 |
9107742 | Cully et al. | Aug 2015 | B2 |
9198789 | Baker et al. | Dec 2015 | B2 |
9375338 | Baker et al. | Jun 2016 | B2 |
9414948 | Baker et al. | Aug 2016 | B2 |
9545326 | Baker et al. | Jan 2017 | B2 |
9549833 | McHugo | Jan 2017 | B2 |
9629733 | Roeder | Apr 2017 | B2 |
9839545 | Baker et al. | Dec 2017 | B2 |
9872787 | Baker et al. | Jan 2018 | B2 |
10182901 | Baker et al. | Jan 2019 | B2 |
10271940 | Baker et al. | Apr 2019 | B2 |
20010011543 | Forsell | Aug 2001 | A1 |
20010020189 | Taylor | Sep 2001 | A1 |
20020032487 | Dua et al. | Mar 2002 | A1 |
20020091395 | Gabbay | Jul 2002 | A1 |
20030040804 | Stack et al. | Feb 2003 | A1 |
20030040808 | Stack et al. | Feb 2003 | A1 |
20030065359 | Weller et al. | Apr 2003 | A1 |
20030109935 | Geitz | Jun 2003 | A1 |
20030199989 | Stack et al. | Oct 2003 | A1 |
20030212450 | Schlick | Nov 2003 | A1 |
20040044357 | Gannoe et al. | Mar 2004 | A1 |
20040087976 | DeVries et al. | May 2004 | A1 |
20040092892 | Kagan et al. | May 2004 | A1 |
20040106987 | Palasis et al. | Jun 2004 | A1 |
20040116999 | Ledergerber | Jun 2004 | A1 |
20040117031 | Stack et al. | Jun 2004 | A1 |
20040122456 | Vahid | Jun 2004 | A1 |
20040138761 | Stack et al. | Jul 2004 | A1 |
20040143342 | Stack et al. | Jul 2004 | A1 |
20040148034 | Kagan et al. | Jul 2004 | A1 |
20040172141 | Stack et al. | Sep 2004 | A1 |
20040210111 | Okada | Oct 2004 | A1 |
20040220682 | Levine et al. | Nov 2004 | A1 |
20050004582 | Edoga et al. | Jan 2005 | A1 |
20050043683 | Ravo | Feb 2005 | A1 |
20050080395 | Levine et al. | Apr 2005 | A1 |
20050096728 | Ramer | May 2005 | A1 |
20050125020 | Meade et al. | Jun 2005 | A1 |
20050177181 | Kagan | Aug 2005 | A1 |
20050192599 | Demarais | Sep 2005 | A1 |
20050192629 | Saadat et al. | Sep 2005 | A1 |
20050197715 | Kugler et al. | Sep 2005 | A1 |
20050228504 | Demarais | Oct 2005 | A1 |
20050245788 | Gerber | Nov 2005 | A1 |
20050245957 | Starkebaum et al. | Nov 2005 | A1 |
20050247320 | Stack et al. | Nov 2005 | A1 |
20050251165 | Vaughan et al. | Nov 2005 | A1 |
20050251176 | Swanstrom et al. | Nov 2005 | A1 |
20050283235 | Kugler et al. | Dec 2005 | A1 |
20060020277 | Gostout et al. | Jan 2006 | A1 |
20060036293 | Whitehurst et al. | Feb 2006 | A1 |
20060064120 | Levine et al. | Mar 2006 | A1 |
20060074473 | Gertner | Apr 2006 | A1 |
20060089571 | Gertner | Apr 2006 | A1 |
20060142844 | Lowe et al. | Jun 2006 | A1 |
20060149307 | Durgin | Jul 2006 | A1 |
20060155375 | Kagan et al. | Jul 2006 | A1 |
20060161139 | Levine et al. | Jul 2006 | A1 |
20060190019 | Gannoe et al. | Aug 2006 | A1 |
20060247721 | Maschino et al. | Nov 2006 | A1 |
20060253131 | Wolniewicz, III | Nov 2006 | A1 |
20060253142 | Bjerken | Nov 2006 | A1 |
20060253191 | Salahieh et al. | Nov 2006 | A1 |
20060264699 | Gertner | Nov 2006 | A1 |
20060265082 | Meade et al. | Nov 2006 | A1 |
20070005147 | Levine et al. | Jan 2007 | A1 |
20070010866 | Dann et al. | Jan 2007 | A1 |
20070010875 | Trout et al. | Jan 2007 | A1 |
20070088428 | Teichman | Apr 2007 | A1 |
20070112409 | Wu et al. | May 2007 | A1 |
20070123994 | Ortiz et al. | May 2007 | A1 |
20070166396 | Badylak et al. | Jul 2007 | A1 |
20070179590 | Lu et al. | Aug 2007 | A1 |
20070198035 | Threlkeld | Aug 2007 | A1 |
20070208429 | Leahy | Sep 2007 | A1 |
20070233221 | Raju | Oct 2007 | A1 |
20070260112 | Rahmani | Nov 2007 | A1 |
20070270742 | Guetty | Nov 2007 | A1 |
20070276432 | Stack et al. | Nov 2007 | A1 |
20070293716 | Baker et al. | Dec 2007 | A1 |
20080015523 | Baker | Jan 2008 | A1 |
20080015618 | Sonnenschein et al. | Jan 2008 | A1 |
20080015633 | Abbott et al. | Jan 2008 | A1 |
20080065122 | Stack et al. | Mar 2008 | A1 |
20080065136 | Young | Mar 2008 | A1 |
20080215076 | Baker | Sep 2008 | A1 |
20080312678 | Pasricha | Dec 2008 | A1 |
20090018389 | Laufer et al. | Jan 2009 | A1 |
20090138071 | Cheng et al. | May 2009 | A1 |
20090177215 | Stack et al. | Jul 2009 | A1 |
20090187230 | Dilorenzo | Jul 2009 | A1 |
20090240340 | Levine et al. | Sep 2009 | A1 |
20090248171 | Levine et al. | Oct 2009 | A1 |
20090270818 | Duke | Oct 2009 | A1 |
20100010298 | Bakos et al. | Jan 2010 | A1 |
20100030017 | Baker et al. | Feb 2010 | A1 |
20100114124 | Kelleher et al. | May 2010 | A1 |
20100114130 | Meade et al. | May 2010 | A1 |
20100256775 | Belhe et al. | Oct 2010 | A1 |
20100280313 | Gasche et al. | Nov 2010 | A1 |
20100305590 | Holmes et al. | Dec 2010 | A1 |
20110004146 | Priplata et al. | Jan 2011 | A1 |
20110009690 | Belhe et al. | Jan 2011 | A1 |
20110264234 | Baker et al. | Oct 2011 | A1 |
20120053653 | Hiernaux et al. | Mar 2012 | A1 |
20120083871 | Ryan | Apr 2012 | A1 |
20120095497 | Babkes et al. | Apr 2012 | A1 |
20120191213 | Baker et al. | Jul 2012 | A1 |
20120191215 | Baker et al. | Jul 2012 | A1 |
20120203061 | Birk | Aug 2012 | A1 |
20130123811 | Baker et al. | May 2013 | A1 |
20130296913 | Foote et al. | Nov 2013 | A1 |
20130310327 | Sambursky et al. | Nov 2013 | A1 |
20130324902 | Miller et al. | Dec 2013 | A1 |
20140135799 | Henderson | May 2014 | A1 |
20140158747 | Measamer et al. | Jun 2014 | A1 |
20140277341 | Havel et al. | Sep 2014 | A1 |
20150039092 | Baker et al. | Feb 2015 | A1 |
20150182239 | Baker et al. | Jul 2015 | A1 |
20160151233 | Baker et al. | Jun 2016 | A1 |
20160228268 | Hingston et al. | Aug 2016 | A1 |
20170172723 | Foote et al. | Jun 2017 | A1 |
20180104080 | Baker et al. | Apr 2018 | A1 |
20190298560 | Belhe et al. | Oct 2019 | A1 |
Number | Date | Country |
---|---|---|
108938163 | Dec 2018 | CN |
0760696 | Aug 2001 | EP |
1808888 | Jul 2007 | EP |
2240215 | Jan 2014 | EP |
2660101 | Jun 1997 | JP |
2006-103873 | Apr 2006 | JP |
2007508053 | Apr 2007 | JP |
2011509758 | Mar 2011 | JP |
2045233 | Oct 1995 | RU |
94026119 | Aug 1996 | RU |
2386455 | Apr 2010 | RU |
WO 9322986 | Nov 1993 | WO |
WO 9412136 | Jun 1994 | WO |
WO 0135834 | May 2001 | WO |
WO 0185034 | Nov 2001 | WO |
WO 02060328 | Aug 2002 | WO |
WO 02094105 | Nov 2002 | WO |
WO 2004019826 | Mar 2004 | WO |
WO 2004064680 | Aug 2004 | WO |
WO 2004064685 | Aug 2004 | WO |
WO 2005037152 | Apr 2005 | WO |
WO 2006044640 | Apr 2006 | WO |
WO 2006078672 | Jul 2006 | WO |
WO 2007092390 | Aug 2007 | WO |
WO 2008100984 | Aug 2008 | WO |
WO 2008101048 | Aug 2008 | WO |
WO 2008101078 | Aug 2008 | WO |
WO 2009048398 | Apr 2009 | WO |
WO 2009091899 | Jul 2009 | WO |
WO 2010117641 | Oct 2010 | WO |
WO 2011056608 | May 2011 | WO |
WO 2011063307 | May 2011 | WO |
WO 2011089601 | Jul 2011 | WO |
WO 2011097209 | Aug 2011 | WO |
WO 2011116025 | Sep 2011 | WO |
WO 2012044917 | Apr 2012 | WO |
WO 2012136249 | Oct 2012 | WO |
WO 2012162114 | Nov 2012 | WO |
WO 2013090190 | Jun 2013 | WO |
WO 2013134227 | Sep 2013 | WO |
WO 2014141239 | Sep 2014 | WO |
WO 2015031077 | Mar 2015 | WO |
WO 2016109346 | Jul 2016 | WO |
WO 2018073752 | Apr 2018 | WO |
WO 2018083632 | May 2018 | WO |
Entry |
---|
International Search Report of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US12/38480, dated Jul. 30, 2012. |
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US12/38480, dated Nov. 29, 2013. |
“Obesity: Super-Sized Medical Device Market”, Start-Up, Mar. 2003, Technology Strategies (Long Article), pp. 1-10 and a cover page. |
Andrew S. Lowe, M.D. and Maria B. Sheridan, M.D., “Esphogeal Stenting”, Seminars in Interventional Radiology, vol. 21, No. 3, 2004, pp. 157-166. |
“Polyflex® Espohageal Stent”, Silicone Covered Stent, Boston Scientific, three pages (2003). |
Andrew F.R. Dixon, Johgn B. Dixon, and Paul E. O'Brien, “Laparoscopic Adjustable Gastric Banding Induces Prolonged Satiety: A Randomized Blind Crossover Study”, The Journal of Clinical Endocrinology & Metabolism , pp. 813-819, 2005. |
Roman, S. et al., “Intragastric balloon for ‘non-morbid’ obesity: a retrospective evaluation of tolerance and efficacy,” Obes. Surg., 2004, 14(4), 539-44, abstract, [on-line], [found Apr. 17, 2009, from Pubmed database]. |
Busetto, L. et al., “Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study,” Obes Surg., 2004, 14(5), 671-6, abstract, [on-line], [found Apr. 17, 2009, from Pubmed database]. |
Summary of Official Action dated Oct. 29, 2009, from the Israel Patent Office in a patent application corresponding to the present application. |
Lowe, Andrew S., M.D. and Sheridan, Maria B., M.D., “Esophageal Stenting,” annotated by Israel Patent Office (2004). |
Abstract and claims of U.S. Pat. No. 6,960,233 annotated by the Israel Patent Office (Nov. 1, 2005). |
Schembre, Drew, “Advances in Esophageal Stenting: the Evolution of Fully Covered Stents for Malignant and Benign Disease,” Adv. Ther., Springer Healthcare, Apr. 1, 2010, pp. 1-13. |
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US08/53912, completed Aug. 19, 2009. |
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US05/36991, completed Mar. 6, 2006. |
S. Fukudo, T. Nomura, M. Hongo, “Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowl syndrome”, Jan. 19, 1998. |
D.G. Maxton, D.F. Martin, P.J. Whorwell, M. Godfrey. “Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms”, Aug. 3, 1990. |
Dixon et al. “Health Outcomes of Severely Obese Type 2 Diabetic Subjects 1 Year After Laparoscopic Adjustable Gastric Banding”. 2002. Diabetic Care 25:358-363. (Year 2002). |
International Search Report of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/IB2017/056838, dated Mar. 7, 2018. |
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/IB2017/056838, dated May 7, 2019. |
Number | Date | Country | |
---|---|---|---|
20200390579 A1 | Dec 2020 | US |
Number | Date | Country | |
---|---|---|---|
60711310 | Aug 2005 | US | |
60636845 | Dec 2004 | US | |
60632147 | Dec 2004 | US | |
60619308 | Oct 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15805495 | Nov 2017 | US |
Child | 17004591 | US | |
Parent | 15211034 | Jul 2016 | US |
Child | 15805495 | US | |
Parent | 14920403 | Oct 2015 | US |
Child | 15211034 | US | |
Parent | 14314444 | Jun 2014 | US |
Child | 14920403 | US | |
Parent | 14142131 | Dec 2013 | US |
Child | 14314444 | US | |
Parent | 13331425 | Dec 2011 | US |
Child | 14142131 | US | |
Parent | 12915952 | Oct 2010 | US |
Child | 13331425 | US | |
Parent | 11463192 | Aug 2006 | US |
Child | 12915952 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2005/036991 | Oct 2005 | US |
Child | 11463192 | US |